Jazz's Enrylaze Approved In EU For Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Treatment
Jazz Pharmaceuticals plc (JAZZ) said that the European Commission granted marketing authorization for Enrylaze for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E.
Source: rttnews.com